Literature DB >> 17976017

Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma.

Jessica Chee1, Jasmine Singh, Anupam Naran, Neil L Misso, Philip J Thompson, Kanti D Bhoola.   

Abstract

Malignant mesothelioma is an aggressive cancer of the pleura that is causally related to exposure to asbestos fibres. The kallikrein serine proteases [tissue (hK1) and plasma (hKB1) kallikreins, and kallikrein-related peptidases (KRP/hK2-15)] and the mitogenic kinin peptides may have a role in tumourigenesis. However, it is not known whether hK1, hKB1, KRP/hK proteins or kinin receptors are expressed in pleural mesotheliomas. The expression of hK1, hKB1, KRP/hK2, 5, 6, 7, 8 and 9, and kinin B(1) and B(2) receptors was assessed in archived selected normal tissue and mesothelioma tumour sections by immunoperoxidase and immunofluorescence labelling. hK1, hKB1 and kinin B(1) and B(2) receptors were expressed in malignant cells of the epithelioid and sarcomatoid components of biphasic mesothelioma tumour cells. The percentage of cells with cytoplasmic and nuclear labelling and the intensity of labelling were similar for hK1, hKB1 and the kinin receptors. KRP/hK2, 6, 8 and 9 were also expressed in the cytoplasm and nuclei of mesothelioma cells, whereas KRP/hK5 and hK7 showed predominantly cytoplasmic localisation. This is a first report, but further studies are required to determine whether these proteins have a functional role in the pathogenesis of mesothelioma and/or may be potential biomarkers for pleural mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976017     DOI: 10.1515/BC.2007.139

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

1.  Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.

Authors:  Rachel M Ostroff; Michael R Mehan; Alex Stewart; Deborah Ayers; Edward N Brody; Stephen A Williams; Stephen Levin; Brad Black; Michael Harbut; Michele Carbone; Chandra Goparaju; Harvey I Pass
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

2.  Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model.

Authors:  Jérôme Côté; Veronica Bovenzi; Martin Savard; Céléna Dubuc; Audrey Fortier; Witold Neugebauer; Luc Tremblay; Werner Müller-Esterl; Ana-Maria Tsanaclis; Martin Lepage; David Fortin; Fernand Gobeil
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

3.  Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.

Authors:  Joshua Wong; Yee Yen Sia; Neil L Misso; Shashi Aggarwal; Angeline Ng; Kanti D Bhoola
Journal:  Patholog Res Int       Date:  2011-09-04

4.  Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.

Authors:  José M Porcel; Aureli Esquerda; Montserrat Martínez-Alonso; Silvia Bielsa; Antonieta Salud
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

5.  Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer.

Authors:  Céléna Dubuc; Martin Savard; Veronica Bovenzi; Andrée Lessard; Audrey Fortier; Jérôme Côté; Witold Neugebauer; Flavio Rizzolio; Sameh Geha; Antonio Giordano; Sylvain Chemtob; Fernand Gobeil
Journal:  Oncotarget       Date:  2018-01-05

Review 6.  Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity.

Authors:  Dora L Vallejo-Ardila; Theodora Fifis; Louise M Burrell; Katrina Walsh; Christopher Christophi
Journal:  Oncotarget       Date:  2018-10-26

7.  The involvement of proteoglycans in the human plasma prekallikrein interaction with the cell surface.

Authors:  Camila Lopes Veronez; Fabio D Nascimento; Katia R B Melo; Helena B Nader; Ivarne L S Tersariol; Guacyara Motta
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.